about
Association between the growth rate of renal cysts/angiomyolipomas and age in the patients with tuberous sclerosis complex.Assessment of tumors in children with tuberous sclerosis: a single centre's experience.TOSCA - first international registry to address knowledge gaps in the natural history and management of tuberous sclerosis complex.Efficacy and safety of a mammalian target of rapamycin inhibitor in pediatric patients with tuberous sclerosis complex: A systematic review and meta-analysisA case of tuberous sclerosis complex with concomitant primary hyperparathyroidism due to parathyroid adenoma: a case report.Prolonging the survival of Tsc2 conditional knockout mice by glutamine supplementation.EFFECTS: an expanded access program of everolimus for patients with subependymal giant cell astrocytoma associated with tuberous sclerosis complexBoerhaave Syndrome, Pneumothorax, and Chylothorax in a Critically Ill Patient with Tuberous Sclerosis Complex.TuberOus SClerosis registry to increase disease Awareness (TOSCA) - baseline data on 2093 patientsEmerging links between homeostatic synaptic plasticity and neurological disease.Is mTOR inhibition a systemic treatment for tuberous sclerosis?Recent Advances and Challenges of mTOR Inhibitors Use in the Treatment of Patients with Tuberous Sclerosis Complex.Dysfunctional mTORC1 Signaling: A Convergent Mechanism between Syndromic and Nonsyndromic Forms of Autism Spectrum Disorder?Familial syndromes associated with intracranial tumours: a review.Synergism between mTOR pathway and ultraviolet radiation in the pathogenesis of squamous cell carcinoma and its implication for solid-organ transplant recipients.Phytochemical modulation of the Akt/mTOR pathway and its potential use in cutaneous disease.Tuberous Sclerosis Complex: An Update for Dermatologists.Phelan McDermid Syndrome: From Genetic Discoveries to Animal Models and Treatment.Seizures in oligodendroglial tumors.Insights into molecular therapy of glioma: current challenges and next generation blueprintEverolimus long-term use in patients with tuberous sclerosis complex: Four-year update of the EXIST-2 study.Hyperactivated mTORC1 downregulation of FOXO3a/PDGFRα/AKT cascade restrains tuberous sclerosis complex-associated tumor development.Tuberous sclerosis complex-associated renal angiomyolipomas: A single center study of 17 consecutive casesEvidence of renal angiomyolipoma neoplastic stem cells arising from renal epithelial cells.Are We Overtreating Renal Angiomyolipoma: A Review of the Literature and Assessment of Contemporary Management and Follow-Up Strategies.Familial genetic tuberous sclerosis complex associated with bilateral giant renal angiomyolipoma: A case report.Management of the "Other" retroperitoneal sarcomas.The effects of everolimus on tuberous sclerosis-associated lesions can be dramatic but may be impermanent.Tuberous sclerosis complex: Five new things.Metabolic Regulation of T Cell Immunity.Rib and vertebral bone fibrous dysplasia in a child with tuberous sclerosis complex.Evolution of a rare ECG pattern in an aggressive case of neonatal tuberous sclerosis complex.A germline MTOR mutation in Aboriginal Australian siblings with intellectual disability, dysmorphism, macrocephaly, and small thoraces.
P2860
Q30789128-0D328DF4-4A81-4ACF-854A-CA9B249E9DD1Q33579243-0D996E38-056B-4A6E-BAB6-E3132E5B3EEFQ34636117-55053EE9-375E-4643-BEBF-9B9FAC55A990Q34795499-59855369-6846-4AA6-BBE7-409C3EF5CC10Q35177019-F010B602-C67A-48AC-868B-5404D09DE294Q35278772-C58CC19A-A6E3-4C77-8B14-1DD350B5CCCAQ36098018-41CD80E7-BA79-4609-8409-A9CC28402A93Q36221024-0C1ABFA5-7810-40B8-9740-5C2E56B30C28Q36241426-52F82DA9-06D6-4322-94EA-A67C140F715AQ37330995-A50A4281-5B2B-4B24-B71B-18F13E77FCDAQ37359517-701C5858-FC40-458D-B284-BC39C8BE19BEQ37721031-19E9D0A6-4A09-4227-89B0-A00F3F1511DCQ37729341-7F8ECE21-214E-400D-B894-78260E024A80Q38160164-AB8D846A-2EC5-4777-9B12-A1AA6C16360EQ38187197-A1A54C79-7F85-40BB-BC07-66FE4450F789Q38223953-9415EA78-7E16-4269-8D0F-7F7CA110992DQ38379999-5C0F100F-22A6-44E2-9579-15AE1B0662E5Q38583174-2B34991B-162D-4C6D-9382-9BFF2FCFF7D7Q38610571-E74511BC-3D35-49B1-8C08-0FC439D3FD8CQ39187306-B76559CE-AAF2-4E76-9CB2-64E7EA0B6FD0Q41326032-5C89185C-1DA9-4CAC-9D1B-95D427B5A128Q41550346-E67F1500-A7DA-477E-9F75-E30685C79870Q42413636-AD18FC02-84FE-49F3-97B9-CAB830271020Q44423986-7BACB940-325D-402A-9F0A-40458AEAE4A5Q47178408-69E3FA6B-C764-45BC-8831-E8C546796765Q47552062-61A801BA-BA33-43D2-A3C7-E0253F10CDC3Q48321145-3AE49682-04CF-4862-90BF-6745D660BD1FQ48560554-E9CFA91F-C68D-4B22-8900-24EC9DE62268Q49360253-314F1F74-2368-44F4-894B-01E291155732Q50217787-274EB14C-86FF-403F-9BBC-2BCEC4DE53F1Q52152043-B08B96F3-6105-45D9-BF00-02E37B956436Q52358941-4B243916-EE0D-4196-9950-A5E7777521F9Q53553888-2A39668E-5588-4D4C-B2A0-FF7066D88B74
P2860
description
2012 nî lūn-bûn
@nan
2012年の論文
@ja
2012年学术文章
@wuu
2012年学术文章
@zh-cn
2012年学术文章
@zh-hans
2012年学术文章
@zh-my
2012年学术文章
@zh-sg
2012年學術文章
@yue
2012年學術文章
@zh
2012年學術文章
@zh-hant
name
mTOR Inhibitors in Tuberous Sclerosis Complex.
@ast
mTOR Inhibitors in Tuberous Sclerosis Complex.
@en
type
label
mTOR Inhibitors in Tuberous Sclerosis Complex.
@ast
mTOR Inhibitors in Tuberous Sclerosis Complex.
@en
prefLabel
mTOR Inhibitors in Tuberous Sclerosis Complex.
@ast
mTOR Inhibitors in Tuberous Sclerosis Complex.
@en
P2860
P1476
mTOR Inhibitors in Tuberous Sclerosis Complex
@en
P2093
Paolo Curatolo
P2860
P304
P356
10.2174/157015912804143595
10.2174/157015912804499537
P577
2012-12-01T00:00:00Z